Abstract
Background
Since the introduction of higher valency pneumococcal conjugate vaccines in 2009, recent estimates on the economic burden of pediatric pneumococcal disease (PD) in Germany have been lacking. This study estimates healthcare resource utilization (HCRU) and medical cost associated with PDs in children
Methods
A nationally representative sample from the Institute for Applied Health Research (InGef) German claims database was used, covering approximately 5% of the total German population. Episodes of pneumococcal pneumonia (PP), all-cause pneumonia (ACP), invasive pneumococcal disease (IPD), and acute otitis media (AOM) in children aged
Results
During 2014–2019, 916,805 children aged
Conclusions
The HCRU and cost per episode of pneumonia and IPD did not vary significantly from 2014–2019, but increased for AOM. The economic burden of pneumonia, IPD, and AOM remains substantial in Germany.
Since the introduction of higher valency pneumococcal conjugate vaccines in 2009, recent estimates on the economic burden of pediatric pneumococcal disease (PD) in Germany have been lacking. This study estimates healthcare resource utilization (HCRU) and medical cost associated with PDs in children
Methods
A nationally representative sample from the Institute for Applied Health Research (InGef) German claims database was used, covering approximately 5% of the total German population. Episodes of pneumococcal pneumonia (PP), all-cause pneumonia (ACP), invasive pneumococcal disease (IPD), and acute otitis media (AOM) in children aged
Results
During 2014–2019, 916,805 children aged
Conclusions
The HCRU and cost per episode of pneumonia and IPD did not vary significantly from 2014–2019, but increased for AOM. The economic burden of pneumonia, IPD, and AOM remains substantial in Germany.
| Original language | English |
|---|---|
| Article number | 7 (2023) |
| Journal | Pneumonia |
| Early online date | 25 Mar 2023 |
| DOIs | |
| Publication status | Published - 25 Mar 2023 |
Bibliographical note
FundingThis research was sponsored and funded by Merck Sharp & Dohme LLC, a
subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Availability of data and materials
The data that support the fndings of this study are stored within the
Institute for Applied Health Research Berlin GmbH (InGef, www.InGef.de).
Restrictions apply to the availability of these data, and they are not publicly
available. Access to patient-level data is not possible and all analyses must
be conducted by InGef. Requests for bespoke analyses/ aggregate results are
reviewed and approved by InGef.
